- Home
- NAUT vs PRQR Comparison
NAUT vs PRQR Comparison
Compare NAUT & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAUT | PRQR |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.6M | 244.1M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NAUT | PRQR |
|---|---|---|
| Price | $1.76 | $1.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $4.00 | ★ $7.25 |
| AVG Volume (30 Days) | 1.3M | ★ 1.6M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $992.86 | $13.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.62 | $1.33 |
| 52 Week High | $4.31 | $3.10 |
Technical Indicators
Market Signals| Indicator | NAUT | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 34.49 | 52.47 |
| Support Level | $0.82 | $1.40 |
| Resistance Level | $1.87 | $2.03 |
| Average True Range (ATR) | 0.17 | 0.18 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 11.32 | 63.03 |
Price Performance
Historical ComparisonAbout NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.